The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Press release from PR Newswire

Amgen Announces Webcast of 2012 First Quarter Financial Results

Thursday, April 19, 2012

Amgen Announces Webcast of 2012 First Quarter Financial Results16:15 EDT Thursday, April 19, 2012THOUSAND OAKS, Calif., April 19, 2012 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that it will report its first quarter financial results on Tuesday, April 24, 2012, after the close of the U.S. financial markets. The announcement will be followed by a conference call with the investment community at 2:00 p.m. Pacific Time.  Participating in the call from Amgen will be Kevin Sharer, chairman and CEO, and other members of Amgen's senior management team.Live audio of the conference call will be simultaneously broadcast over the Internet and will be available to members of the news media, investors and the general public. The webcast of the conference, as with other selected presentations regarding developments in Amgen's business given by management at certain investor and medical conferences, can be found on Amgen's website, www.amgen.com, under Investors. Information regarding presentation times, webcast availability and webcast links are noted on Amgen's Investor Relations Events Calendar. The webcast will be archived and available for replay for at least 30 days after the event.About AmgenAmgen discovers, develops, manufactures and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe, effective medicines from lab to manufacturing plant to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, bone disease and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives. To learn more about our pioneering science and vital medicines, visit www.amgen.com.  Follow us on www.twitter.com/amgen. CONTACT: Amgen, Thousand OaksChristine Regan, 805-447-5476 (media)Arvind Sood, 805-447-1060 (investors)(Logo: http://photos.prnewswire.com/prnh/20081015/AMGENLOGO) SOURCE Amgen